NCT00708721 · OUTCOME

The Effect of Low Dose Daily Oral Clofarabine on Global Methylation in Patients With MDS.

Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia · Source last updated 2017-06-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: through end of treatment

What was measured

Potential genomic changes following low dose daily oral clofarabine administration will be assessed.

Analysis population: Data were not collected and the outcome measure was not analyzed

Groups in this outcome

All Patients

All participants enrolled.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Patients	0

Reported measurements

Source class 1

Values in Not reported · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
All Patients	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
0

denoms

counts
group Id
OG000
value
0
units
Participants

description

Potential genomic changes following low dose daily oral clofarabine administration will be assessed.

groups

description
All participants enrolled.
id
OG000
title
All Patients

population Description

Data were not collected and the outcome measure was not analyzed

reporting Status

POSTED

time Frame

through end of treatment

title

The Effect of Low Dose Daily Oral Clofarabine on Global Methylation in Patients With MDS.

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice